These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23268322)

  • 1. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation.
    Lin CH; Liu JM; Lu YS; Lan C; Lee WC; Kuo KT; Wang CC; Chang DY; Huang CS; Cheng AL
    J Clin Pathol; 2013 Feb; 66(2):140-5. PubMed ID: 23268322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
    Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
    PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
    Holst F; Stahl PR; Ruiz C; Hellwinkel O; Jehan Z; Wendland M; Lebeau A; Terracciano L; Al-Kuraya K; Jänicke F; Sauter G; Simon R
    Nat Genet; 2007 May; 39(5):655-60. PubMed ID: 17417639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
    Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
    Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study.
    Moelans CB; Monsuur HN; de Pinth JH; Radersma RD; de Weger RA; van Diest PJ
    Anal Cell Pathol (Amst); 2010; 33(1):13-8. PubMed ID: 20966540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
    Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
    BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan.
    Chen JR; Hsieh TY; Chen HY; Yeh KY; Chen KS; ChangChien YC; Pintye M; Chang LC; Hwang CC; Chien HP; Hsu YC
    Virchows Arch; 2014 Jun; 464(6):689-99. PubMed ID: 24756215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study.
    Ooi A; Inokuchi M; Harada S; Inazawa J; Tajiri R; Kitamura SS; Ikeda H; Kawashima H; Dobashi Y
    J Pathol; 2012 May; 227(1):8-16. PubMed ID: 22170254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry.
    Laenkholm AV; Knoop A; Ejlertsen B; Rudbeck T; Jensen MB; Müller S; Lykkesfeldt AE; Rasmussen BB; Nielsen KV
    Mol Oncol; 2012 Aug; 6(4):428-36. PubMed ID: 22626971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions.
    Lebeau A; Grob T; Holst F; Seyedi-Fazlollahi N; Moch H; Terracciano L; Turzynski A; Choschzick M; Sauter G; Simon R
    J Pathol; 2008 Oct; 216(2):151-7. PubMed ID: 18720455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOP2A gene copy number change in breast cancer.
    Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
    J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous.
    Moelans CB; Holst F; Hellwinkel O; Simon R; van Diest PJ
    PLoS One; 2013; 8(12):e84189. PubMed ID: 24367641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESR1 amplification in endometrial carcinomas: hope or hyperbole?
    Tan DS; Lambros MB; Marchiò C; Reis-Filho JS
    J Pathol; 2008 Nov; 216(3):271-4. PubMed ID: 18788074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Singer CF; ; Holst F; Steurer S; Burandt EC; Lax SF; Jakesz R; Rudas M; Stöger H; Greil R; ; Sauter G; Filipits M; ; Simon R; Gnant M;
    Clin Cancer Res; 2022 Sep; 28(18):4112-4120. PubMed ID: 35920686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
    Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
    PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
    Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
    Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.